Cogent Biosciences (COGT) total liabilities

Total liabilities · fiscal 2025
$301.24M

Cogent Biosciences (COGT) had total liabilities of $301.24M at the end of fiscal 2025 (December 31, 2025). That is 320.7% higher than the $71.61M of fiscal 2024. Figures as of 19 Nov 2026, 00:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$301.24M
Change on fiscal 2024
+320.7%
Growth, 5 years
+79.3% a year
Highest on record
$301.24Mfiscal 2025
Lowest on record
$16.25Mfiscal 2020
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Cogent Biosciences total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 79.3% a year. Across the 9 fiscal years on record (2017–2025), the highest was $301.24M in fiscal 2025 and the lowest $16.25M in fiscal 2020.

History · 9 fiscal years

Total liabilities by fiscal year

Cogent Biosciences total liabilities, year by year

Cogent Biosciences (COGT) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$301.24M 320.7% up
2024$71.61M 28.7% up
2023$55.64M 23.4% up
2022$45.08M 151.7% up
2021$17.91M 10.2% up
2020$16.25M 8.0% down
2019$17.66M 31.3% down
2018$25.69M 23.5% up
2017$20.81M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Cogent Biosciences and comparable companies
CompanyTotal liabilitiesFiscal year
Teleflex TFX$3.82B2025
Mirum Pharmaceuticals MIRM$528.12M2025
Veradermics MANE$9.16M2025
Grifols GRFS€12.11B2025
Cogent Biosciences COGT$301.24M2025
GRAIL GRAL$344.15M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on COGT

Cogent Biosciences, figure by figure

Cogent Biosciences (COGT) overview: price, valuation and scorecardAll health care companies by market value

Cogent Biosciences total liabilities: questions and answers

How large are Cogent Biosciences's total liabilities?

Cogent Biosciences (COGT) had total liabilities of $301.24M at the end of fiscal 2025 (December 31, 2025). That is 320.7% higher than the $71.61M of fiscal 2024.

What is the growth rate of Cogent Biosciences's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 79.3% a year.

What are the highest and lowest total liabilities figures on record for Cogent Biosciences?

Across the 9 fiscal years on record (2017–2025), the highest was $301.24M in fiscal 2025 and the lowest $16.25M in fiscal 2020.

How is Cogent Biosciences's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Cogent Biosciences it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cogent Biosciences (COGT) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/COGT/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.